Last reviewed · How we verify
rF1V vaccine
rF1V vaccine is a Biologic drug developed by DynPort Vaccine Company LLC, A GDIT Company. It is currently in Phase 2 development. Also known as: Recombinant Plague Vaccine rF1V.
The rF1V vaccine is a vaccine component that induces an immune response, classified as a biological vaccine. It is being studied for its immunogenicity, safety, and tolerability in preventing vaccine-preventable diseases, including pneumonic plague, in adults aged 18 to 55 years.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | rF1V vaccine |
|---|---|
| Also known as | Recombinant Plague Vaccine rF1V |
| Sponsor | DynPort Vaccine Company LLC, A GDIT Company |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age (PHASE2)
- Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant (PHASE2)
- Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers (PHASE2)
- Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rF1V vaccine CI brief — competitive landscape report
- rF1V vaccine updates RSS · CI watch RSS
- DynPort Vaccine Company LLC, A GDIT Company portfolio CI
Frequently asked questions about rF1V vaccine
What is rF1V vaccine?
Who makes rF1V vaccine?
Is rF1V vaccine also known as anything else?
What development phase is rF1V vaccine in?
Related
- Manufacturer: DynPort Vaccine Company LLC, A GDIT Company — full pipeline
- Also known as: Recombinant Plague Vaccine rF1V
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing